Header Logo

Connection

Joan Swearer to Alzheimer Disease

This is a "connection" page, showing publications Joan Swearer has written about Alzheimer Disease.
Connection Strength

0.601
  1. Swearer JM, O'Donnell BF, Parker M, Kane KJ, Drachman DA. Psychological features in persons at risk for familial Alzheimer's disease. Am J Alzheimers Dis Other Demen. 2001 May-Jun; 16(3):157-62.
    View in: PubMed
    Score: 0.119
  2. Swearer JM, O'Donnell BF, Ingram SM, Drachman DA. Rate of progression in familial Alzheimer's disease. J Geriatr Psychiatry Neurol. 1996 Jan; 9(1):22-5.
    View in: PubMed
    Score: 0.082
  3. Swearer JM. Methodological issues in the management of behavioral disturbances in dementia. Int Psychogeriatr. 1996; 8 Suppl 1:59-62.
    View in: PubMed
    Score: 0.082
  4. Drachman DA, O'Donnell BF, Lew RA, Swearer JM. The prognosis in Alzheimer's disease. 'How far' rather than 'how fast' best predicts the course. Arch Neurol. 1990 Aug; 47(8):851-6.
    View in: PubMed
    Score: 0.056
  5. Evans BA, Evans JE, Baker SP, Kane K, Swearer J, Hinerfeld D, Caselli R, Rogaeva E, St George-Hyslop P, Moonis M, Pollen DA. Long-term statin therapy and CSF cholesterol levels: implications for Alzheimer's disease. Dement Geriatr Cogn Disord. 2009; 27(6):519-24.
    View in: PubMed
    Score: 0.052
  6. Swearer JM, Drachman DA, O'Donnell BF, Mitchell AL. Troublesome and disruptive behaviors in dementia. Relationships to diagnosis and disease severity. J Am Geriatr Soc. 1988 Sep; 36(9):784-90.
    View in: PubMed
    Score: 0.049
  7. Hinerfeld DA, Moonis M, Swearer JM, Baker SP, Caselli RJ, Rogaeva E, St George-Hyslop P, Pollen DA. Statins differentially affect amyloid precursor protein metabolism in presymptomatic PS1 and non-PS1 subjects. Arch Neurol. 2007 Nov; 64(11):1672-3.
    View in: PubMed
    Score: 0.047
  8. Moonis M, Swearer JM, Dayaw MP, St George-Hyslop P, Rogaeva E, Kawarai T, Pollen DA. Familial Alzheimer disease: decreases in CSF Abeta42 levels precede cognitive decline. Neurology. 2005 Jul 26; 65(2):323-5.
    View in: PubMed
    Score: 0.040
  9. Lippa CF, Swearer JM, Kane KJ, Nochlin D, Bird TD, Ghetti B, Nee LE, St George-Hyslop P, Pollen DA, Drachman DA. Familial Alzheimer's disease: site of mutation influences clinical phenotype. Ann Neurol. 2000 Sep; 48(3):376-9.
    View in: PubMed
    Score: 0.028
  10. Lippa CF, Saunders AM, Smith TW, Swearer JM, Drachman DA, Ghetti B, Nee L, Pulaski-Salo D, Dickson D, Robitaille Y, Bergeron C, Crain B, Benson MD, Farlow M, Hyman BT, George-Hyslop SP, Roses AD, Pollen DA. Familial and sporadic Alzheimer's disease: neuropathology cannot exclude a final common pathway. Neurology. 1996 Feb; 46(2):406-12.
    View in: PubMed
    Score: 0.021
  11. O'Donnell BF, Drachman DA, Lew RA, Swearer JM. Measuring dementia: assessment of multiple deficit domains. J Clin Psychol. 1988 Nov; 44(6):916-23.
    View in: PubMed
    Score: 0.013
  12. Klunk WE, Price JC, Mathis CA, Tsopelas ND, Lopresti BJ, Ziolko SK, Bi W, Hoge JA, Cohen AD, Ikonomovic MD, Saxton JA, Snitz BE, Pollen DA, Moonis M, Lippa CF, Swearer JM, Johnson KA, Rentz DM, Fischman AJ, Aizenstein HJ, DeKosky ST. Amyloid deposition begins in the striatum of presenilin-1 mutation carriers from two unrelated pedigrees. J Neurosci. 2007 Jun 06; 27(23):6174-84.
    View in: PubMed
    Score: 0.011
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.